Alyeska Investment Group L.P. Grows Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Alyeska Investment Group L.P. raised its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 39.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 351,348 shares of the company's stock after buying an additional 100,000 shares during the quarter. Alyeska Investment Group L.P. owned about 0.51% of EyePoint Pharmaceuticals worth $2,618,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Legal & General Group Plc boosted its holdings in EyePoint Pharmaceuticals by 4.4% during the 4th quarter. Legal & General Group Plc now owns 46,263 shares of the company's stock valued at $345,000 after acquiring an additional 1,932 shares during the period. Summit Investment Advisors Inc. grew its stake in EyePoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after acquiring an additional 1,940 shares in the last quarter. Invesco Ltd. increased its position in shares of EyePoint Pharmaceuticals by 16.1% during the fourth quarter. Invesco Ltd. now owns 15,657 shares of the company's stock worth $117,000 after acquiring an additional 2,177 shares during the period. Teacher Retirement System of Texas raised its stake in shares of EyePoint Pharmaceuticals by 22.4% during the fourth quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company's stock valued at $113,000 after acquiring an additional 2,782 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in shares of EyePoint Pharmaceuticals by 3.5% in the fourth quarter. Swiss National Bank now owns 100,000 shares of the company's stock valued at $745,000 after purchasing an additional 3,400 shares during the period. Institutional investors own 99.41% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on EYPT shares. HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Chardan Capital decreased their price target on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday. Finally, StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $25.29.

EyePoint Pharmaceuticals Price Performance

Shares of EYPT stock traded up $0.04 during trading on Monday, hitting $5.85. 170,928 shares of the stock traded hands, compared to its average volume of 810,176. The firm has a market capitalization of $402.82 million, a P/E ratio of -2.93 and a beta of 1.58. EyePoint Pharmaceuticals, Inc. has a 52-week low of $3.91 and a 52-week high of $13.98. The firm's fifty day moving average price is $6.02 and its 200-day moving average price is $7.49.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $24.50 million for the quarter, compared to the consensus estimate of $8.84 million. As a group, equities research analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.